This study proposes: (1) Monitoring thyroid hormone sensitivity indices in high-risk HUA populations (such as those with metabolic syndrome) could facilitate early risk stratification; (2) Lipid-lowering treatment for patients with subclinical thyroid dysfunction may render “metabolic cascade benefits,” improving uric acid metabolism; (3) The applicability of current thyroid function reference ranges in assessing metabolic risk necessitates reevaluation (21). This evidence concerns the gene TG and metabolic syndrome.